Lupin Ltd.

Financial

	Lupin	Zydus Lifesciences	Abbott India
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	441.0 .	486.0 .	n/a
Number of ANDA's Approved By USFDA	340.0 .	421.0 .	n/a
Domestic Sales Growth - YoY	7.0 %	6.7 %	8.2 %
US DMF Filings	157.0 .	147.0 .	n/a
R&D as a % of Total Sales	9.6 %	8.1 %	0.02 %
Financials
5 yr Average ROE	6.43 %	18.47 %	30.11 %
5yr average Equity Multiplier	1.73	1.52	1.43
5yr Average Asset Turnover Ratio	0.75	0.66	1.14
5yr Avg Net Profit Margin	5.06 %	19.02 %	18.53 %
Price to Book	4.95	3.99	16.9
P/E	25.96	21.1	50.59
5yr Avg Cash Conversion Cycle	-84.38 Days	-84.89 Days	-46.68 Days
Inventory Days	53.29 Days	36.38 Days	45.22 Days
Days Receivable	50.0 Days	36.93 Days	19.34 Days
Days Payable	160.27 Days	160.15 Days	109.21 Days
5yr Average Interest Coverage Ratio	6.26	30.19	97.37
5yr Avg ROCE	10.02 %	19.65 %	38.77 %
5yr Avg Operating Profit Margin	14.15 %	24.4 %	23.42 %
5 yr average Debt to Equity	0.3	0.17	0.0
5yr CAGR Net Profit	21.95 %	16.23 %	15.41 %
5yr Average Return on Assets	3.91 %	12.22 %	21.03 %
Shareholdings
Promoter Holding	46.9 %	74.99 %	74.99 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.2 %	0.11 %	0.0
Change in Mutual Fund Holding (3 Yrs)	3.49 %	0.94 %	2.93 %

Business

	Lupin	Zydus Lifesciences	Abbott India
Product Wise Break-Up	Product Wise Break-Up Advanced Markets Formulations 45.0 India 34.0 Emerging Market 12.0 Active Pharmaceutical Ingredient (API) 9.0 NCD 1.0 USA 0 Developed Markets 0 Generic FDF 0 Custom Synthesis 0 IM Formulations 0 Emerging Markets 0 Europe Formulatios 0 Alliances 0 Wellness 0 Animal Health 0 India Formulations 0 US Formulations 0 Vitamin, Minerals & Nutrition 0 Hepatoprotectives 0 Hormones 0 Anti Diabetic 0 Central Nervous System 0 Respiratory 0 Vaccines 0 cardiovascular system 0 Derma 0 Anti-Infectives 0 Metabolic 0 Women`s health 0 Gastro Intestinal 0 Pain 0	Product Wise Break-Up NCD 0 cardiovascular system 0 Advanced Markets Formulations 0 Respiratory 0 Metabolic 0 Emerging Markets 0 Hepatoprotectives 0 Anti-Infectives 0 Women`s health 0 Emerging Market 0 USA 0 Central Nervous System 0 Vaccines 0 Derma 0 Wellness 13.86 Custom Synthesis 0 Gastro Intestinal 0 India 0 EMB Formulations 8.91 Pain 0 Animal Health 0 Active Pharmaceutical Ingredient (API) 0 Developed Markets 0 Vitamin, Minerals & Nutrition 0 Europe Formulatios 0 India Formulations 24.75 Generic FDF 0 Anti Diabetic 0 Alliance 0.45 Hormones 0 US Formulations 49.5 Others 2.53	Product Wise Break-Up NCD 0 cardiovascular system 0 Advanced Markets Formulations 0 Respiratory 0 Metabolic 0 Emerging Markets 0 Hepatoprotectives 0 Anti-Infectives 0 Women`s health 0 Emerging Market 0 USA 0 Central Nervous System (CNS) 12.65 Vaccines 0 Derma 0 Wellness 0 Custom Synthesis 0 Gastro Intestinal 25.46 India 0 IM Formulations 0 Pain 0 Animal Health 0 Active Pharmaceutical Ingredient (API) 0 Developed Markets 0 Vitamin, Minerals & Nutrition 0 Europe Formulatios 0 India Formulations 0 Generic FDF 0 Anti Diabetic 42.82 Alliances 0 Hormones 11.59 US Formulations 0 Others 7.48
Segment Break-Up	Segment Break-Up Pharmaceuticals 99.44 Research Services & Sale of IP`s 0 Consumer Products 0 Others 0.56	Segment Break-Up OTC 13.95 Research Services & Sale of IP`s 0 Pharmaceuticals 86.05	-
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Cardiac Science 24.0 Anti - Diabetes 22.0 Respiratory Systems 14.0 Gastro Intestinal 7.0 Gynecology 6.0 Anti-Infective 6.0 Vitamins / Minerals / Nutrients 5.0 Anti-Tuberculosis 4.0 Central Nervous System (CNS) 4.0 Pain Management 3.0 Others 5.0	-	-
Location Wise Break-Up	Location Wise Break-Up USA 36.0 India 34.0 Developed Markets 13.0 EMEA 11.0 API 5.0 Japan 0 Rest of the World 0 Others 1.0	Location Wise Break-Up India 41.0 Japan 0 USA 44.89 Rest of the World 0 Developed Markets 0 EMEA 0 API 0 Others 14.11	Location Wise Break-Up India 98.65 Japan 0 USA 0 Rest of the World 1.35 Developed Markets 0 EMEA 0 API 0
Acute vs Chronic	Acute vs Chronic Chronic 63.1 Acute 36.9 Sub-chronic 0	-	Acute vs Chronic Sub-chronic 27.0 Acute 27.0 Chronic 46.0

Lupin Ltd.

SIGN UP FOR FREE